Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Manulife entered the second half of 2026 with positive operating momentum: Q2 core EPS increased 16% year over year, APE sales increased 21%, new business CSM increased 16%, and core ROE reached 16.3%. The refreshed strategy provides a measurable path toward at least 18% core ROE in 2027, while the planned Indian life-insurance joint venture adds a prospective long-duration growth platform. Offsetting these merits, Global Wealth and Asset Management net inflows slowed to C$0.4 billion from C$0.9 billion in the comparable quarter, and execution is still required to close the gap between current core ROE and the 2027 target.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026
Low · most bearish analyst$34.45
Mean target$34.45
High · most bullish analyst$34.45
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$34.4520%

Insurance new-business momentum stalls, Global Wealth and Asset Management moves into net outflows, or operating execution leaves full-year 2027 core ROE below 18%. These outcomes would undermine the central strategic target and weaken the operating case.

Base CaseCentral scenario
$34.4555%
Matches the consensus mean

Insurance new-business growth moderates from Q2 2026 levels but remains positive, core ROE progresses toward the 2027 target, and Global Wealth and Asset Management continues to generate modest positive net inflows.

Bull CaseUpside scenario
$34.4525%

Insurance demand and new-business economics remain strong, core ROE reaches or exceeds 18% by full-year 2027, wealth-management flows remain positive, and the Mahindra Manulife insurance venture advances successfully.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Q2 2026 showed broad insurance momentum, including 21% APE-sales growth, 16% new-business CSM growth, and 10% new-business-value growth year over year.
  • The refreshed strategy establishes measurable objectives, including core ROE of at least 18% by 2027, cumulative remittances above C$22 billion over 2024-2027, and a 50% Asia contribution to core earnings.
Sign in / Sign up to read more
Key Investment Risks
  • Q2 2026 core ROE of 16.3% remained below the company's full-year 2027 target of at least 18%, leaving execution risk.
  • Global Wealth and Asset Management net inflows declined to C$0.4 billion in Q2 2026 from C$0.9 billion in Q2 2025.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.